SIGA-246 to Treat Smallpox

NCT00303225 | Withdrawn Phase 1

• 2 other identifiers: 06011406-I-0114
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This study will test an experimental antiviral drug called SIGA-246 for use against the smallpox virus (variola). Although smallpox has been universally eradicated, it could possibly be brought back as a bioweapon. In the event of a smallpox attack, it would be best to have an antiviral medication in addition to the smallpox vaccine. SIGA-246 has shown to have activity against other viruses from the same family (orthopoxvirus) that smallpox belongs to. Healthy volunteers who are 18-50 years of age and are not pregnant or breastfeeding may be eligible for this study. Candidates are screened with a medical history and physical examination, blood and urine tests, and an electrocardiogram. Participants are randomly assigned to receive a one-time dose of SIGA-246 (either 500 mg, 1000 mg, or 2000 mg) or a placebo (sugar pill) taken by mouth. They report to the clinic in the morning for the following procedures:

• Insertion of intravenous (IV) line in the forearm.
• Blood and urine tests before taking the study drug.
• Drug administration within 30 minutes of eating a light breakfast.
• Blood sampling from the IV line at 30 minutes and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 5 and 6, 10 and 12 hours after taking SIGA-246 to determine how the drug is absorbed, distributed, broken down and excreted. Samples are also collected by needle stick at 24 and 48 hours for the same tests.
• Electrocardiogram at 2 hours and 24 hours after taking SIGA-246.
• 24-hour urine collection after taking the SIGA-246.
• Complete diary card at home for 7 days after taking the SIGA-246.
• Follow-up visits at about 2 weeks and about 4 weeks after taking SIGA-246.
• Checks for health changes or problems at every visit.

Conditions

Vaccinia

Keywords

Biodefense; Smallpox; Monkeypox; Vaccinia; Prophylaxis; Healthy Volunteer; HV

Interventions

Vaccine: SIGA-246 DRUG

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• A participant must meet all of the following criteria:
• to 50 years old, inclusive.
• Available for clinical follow-up for the duration of the study.
• Able and willing to give written informed consent.
• In good general health without clinically significant medical history.
• Be able to refrain from taking any medications for 48 hours after study agent administration.
• Have adequate venous access.
• Physical examination and laboratory results without clinically significant findings within the 28 days prior to receipt of study drug (i.e., satisfactorily completed screening).
• Laboratory criteria within 28 days prior to receipt of study drug:
• Hemoglobin within institutional normal range.
• WBC within institutional normal range.
• Absolute neutrophil count (ANC) within institutional normal range.
• Total lymphocyte count within institutional normal range.
• Platelets within institutional normal range.
• ALT (SGPT) within institutional norm range. If the ALT is not within normal limits, it may be repeated once within the 28 days prior to receipt of the study drug.

You may not qualify if:

• A volunteer will be excluded if one or more of the following conditions apply:
• Woman who is breast-feeding or planning to become pregnant prior to or during the 4 weeks of study participation.
• Volunteer is on any concomitant medications, including over the counter medications or herbal supplements, for 14 days before the administration of the study agent.
• Volunteer has a history of any clinically significant conditions including:
• Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids.
• Diabetes mellitus (type I or II), with the exception of gestational diabetes.
• History of thyroidectomy or thyroid disease that required medication within the past 12 months.
• Serious angioedema episodes within the previous three years or requiring medication in the previous two years.
• Hypertension requiring medication.
• Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
• Malignancy that is active, or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study.
• Seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring treatment within the last 3 years.
• Volunteer has:
• Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
• Inability to swallow study medication.

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (1)

National Institute of Allergy and Infectious Diseases (NIAID)

Bethesda, Maryland, 20892, United States

Location

MeSH Terms

Conditions

Vaccinia; Smallpox; Mpox, Monkeypox

Condition Hierarchy (Ancestors)

Poxviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Primate Diseases; Animal Diseases; Rodent Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: March 14, 2006
• First Posted: March 15, 2006
• Study Start: March 13, 2006
• Study Completion: August 4, 2006
• Last Updated: July 2, 2017

Record last verified: 2006-08-04

Locations

US (1)